Search the Newsreel

Atea Pharmaceuticals Inc (AVIR) Valuation: PE, PB & Fair Value Analysis

This article analyzes the valuation of Atea Pharmaceuticals Inc (AVIR), noting its current valuation score of 6.78, ranking it 260 out of 385 in the Biotechnology & Medical Research industry. It highlights AVIR's current P/E ratio of -2.22, which is significantly below its recent …

Atea Pharmaceuticals (AVIR) Projected to Post Earnings on Thursday

StealthGas Inc (GASS) Institutional Confidence

This article analyzes StealthGas Inc.'s (GASS) institutional confidence based on its shareholding score and proportion. The company holds a score of 3.00, ranking 63 out of 88 in its industry, with a recent decrease in institutional shareholding proportion to 37.27%. James Simons is identified …

NetEase Inc (NTES) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of NetEase Inc (NTES), detailing its current price momentum score, support and resistance levels, and indicator and moving average readings. It highlights that NTES is suitable for range-bound swing trading and includes FAQs about technical ratings, moving averages, …

Nomura Sticks to Its Buy Rating for Netease Inc (9999)

Nomura analyst maintained a Buy rating on Netease Inc with a price target of HK$155.00, while the company's shares closed at HK$191.00. The analyst consensus for Netease Inc is a Strong Buy, with an average price target of HK$244.32, indicating a potential 27.92% upside. …

Fund Update: 7,212 NETEASE (NTES) shares added to Guinness Asset Management LTD portfolio

Guinness Asset Management LTD has increased its holdings in NETEASE (NTES) by 7,212 shares, according to a recent SEC 13F filing for the reporting period ending June 30, 2026. The article also details recent hedge fund activity, showing 189 institutional investors adding shares and …

NetEase (NASDAQ:NTES) Downgraded to "Hold" Rating by Zacks Research

Zacks Research has downgraded NetEase (NASDAQ:NTES) from a "strong-buy" to a "hold" rating, though the overall analyst consensus remains a "Moderate Buy" with an average price target of $158.38. The downgrade follows recent insider selling by General Counsel Paul William Boltz, Jr. who sold …

Analysts Are Bullish on These Healthcare Stocks: Opko Health (OPK), Atea Pharmaceuticals (AVIR)

The article highlights bullish sentiments from analysts on several healthcare stocks, including Opko Health (OPK), Atea Pharmaceuticals (AVIR), and Monte Rosa Therapeutics (GLUE). H.C. Wainwright and Piper Sandler reiterated Buy ratings for Opko Health, William Blair maintained a Buy rating for Atea Pharmaceuticals, and …

TEAMLEASE: Q1FY27 revenue rose 6% YoY, PBT up 38% YoY, and a ₹238 crore buyback was completed

TeamViewer SE (TMVWF) Half Year 2026 Earnings Call Highlights: Strategic Partnerships and AI ...

This article first appeared on GuruFocus. Release Date: July 28, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points TeamViewer SE (TMVWF) reported a strong adjusted EBITDA margin of 43.2%, demonstrating financial discipline. The …

StealthGas, Inc. (NASDAQ:GASS) Short Interest Down 48.6% in July

StealthGas, Inc. (NASDAQ:GASS) experienced a significant 48.6% decrease in short interest in July, with the total dropping to 53,573 shares as of July 15th. This represents approximately 0.2% of the company's outstanding stock, with a short-interest ratio of 0.4 days. The shipping company also …

Earnings To Watch: TeamLease Services Ltd (NSE:TEAMLEASE) Q1 202

Atea drops despite late-stage trial win for hepatitis C therapy

Atea Pharmaceuticals (AVIR) announced positive topline data from its Phase 3 C-BEYOND study for its lead candidate BEM/RZR, demonstrating a late-stage trial win against chronic hepatitis C. Despite this clinical success, the company's stock traded lower on Tuesday. The drug is an antiviral therapy …

Atea Pharmaceuticals Reports Positive Topline Results From C-BEYOND Phase 3 Trial Evaluating Bemnifosbuvir/Ruzasvir For Hepatitis C Virus

Atea Pharmaceuticals announced positive topline results from its C-BEYOND Phase 3 trial, showing its bemnifosbuvir/ruzasvir (BEM/RZR) combination achieved statistical non-inferiority against the standard treatment for chronic hepatitis C virus (HCV) infection. The BEM/RZR regimen demonstrated robust sustained virologic response rates, including in cirrhotic and …

Atea Pharmaceuticals Reports Positive Phase 3 C-BEYOND Results for Bemnifosbuvir/Ruzasvir in Hepatitis C, Achieving Non-Inferiority to Epclusa

Atea Pharmaceuticals announced positive results from its C-BEYOND Phase 3 clinical trial, demonstrating that bemnifosbuvir/ruzavir (BEM/RZR) achieved non-inferiority compared to standard-of-care sofosbuvir/velpatasvir (SOF/VEL) for chronic hepatitis C. BEM/RZR showed a high sustained virologic response rate of 93.9% with a shorter 8-week treatment duration for …

Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus

Atea Pharmaceuticals announced positive topline results from its Phase 3 C-BEYOND trial, demonstrating that its BEM/RZR treatment for hepatitis C virus (HCV) achieved statistical non-inferiority compared to a standard-of-care treatment. The study showed high cure rates, with a 93.9% sustained virologic response, and highlighted …

NetEase, Inc. $NTES Shares Purchased by Lazard Asset Management LLC

Lazard Asset Management LLC significantly increased its stake in NetEase, Inc. (NASDAQ:NTES) by 64.2% in the first quarter, now owning 581,720 shares valued at $65.1 million. Several other institutional investors also adjusted their positions, with UBS AM increasing its holdings by a substantial 68,860.6%. …

Teamviewer weiter mit Umsatzrückgang - Prognose steht aber ()

AVIR|Atea Pharmaceuticals Inc|Price:4.810|Chg%:+0.080

This article provides a comprehensive stock analysis of Atea Pharmaceuticals Inc (AVIR), detailing its TradingKey Stock Score, financial health, valuation, earnings forecast, price momentum, institutional confidence, and risk assessment. Key insights highlight the company's stable fundamentals, high growth potential, fair valuation, and strong institutional …

GASS|StealthGas Inc|Price:8.960|Chg%:+0.100

This article provides a comprehensive stock analysis of StealthGas Inc (GASS), highlighting its strong fundamentals, high growth potential, and fair valuation within the Oil & Gas Related Equipment and Services industry. Despite healthy market performance, technical indicators suggest a sideways trading pattern, suitable for …

StealthGas Inc (GASS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for StealthGas Inc (GASS), detailing its financial performance across different business segments for fiscal years 2021-2024. The primary revenue source is Time Charter revenues, accounting for over 91% of the total, followed by Voyage Charter and other income. …

Atea Pharmaceuticals Inc (AVIR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey provides a revenue breakdown for Atea Pharmaceuticals Inc (AVIR), but notes that relevant data for business segments and regional revenue have not yet been disclosed by the company for fiscal years 2020 through 2022. It briefly shows the company's current …

Atea Pharmaceuticals Inc (AVIR) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Atea Pharmaceuticals Inc (AVIR), highlighting its current earnings forecast score and analyst ratings. Based on three analysts, the average price target for AVIR is $6.00, with a consensus "Buy" rating. The article also discusses past EPS performance …

Eneba Partners with Marvel Rivals Publisher as Official NetEase Pay Gift Card Distributor

Eneba, a rapidly growing digital entertainment marketplace, has officially partnered with NetEase Games to become a distributor of NetEase Pay gift cards. This collaboration allows Eneba to offer NetEase Pay gift cards in various USD denominations globally, enabling users to make in-game purchases for …

Arrowstreet Capital Limited Partnership Sells 611,697 Shares of NetEase, Inc. $NTES

Arrowstreet Capital Limited Partnership significantly reduced its stake in NetEase, Inc. (NASDAQ:NTES) by 50.2% during the first quarter, selling 611,697 shares and now owning 606,559 shares valued at $67,898,000. This institutional selling comes amidst other hedge funds adjusting their positions, and analysis on NetEase …

TISI|Team Inc|Price:16.990|Chg%:+0.350

Team Inc. (TISI) is a provider of specialty industrial services, including inspection, heat treating, and mechanical services. The company's segments are Inspection and Heat Treating (IHT) and Mechanical Services (MS), serving various sectors like process, pipeline, power, and aerospace. As of Q1 2026, institutional …

NetEase (NTES) Expected Revenue Growth Amid Investment Losses

Dhunseri Tea reports ₹59 lakh profit on asset sales, declares ₹2 dividend

Here's What We Like About United Nilgiri Tea Estates' (NSE:UNITEDTEA) Upcoming Dividend

[Press release] Atea Pharmaceuticals initiates first-in-human Phase 1 clinical trial of AT-587 for the treatment of hepatitis E virus

Atea Pharmaceuticals has announced the start of a first-in-human Phase 1 clinical trial for AT-587, an oral antiviral nucleotide analog designed to treat hepatitis E virus (HEV). The trial will assess the safety, tolerability, and pharmacokinetics of AT-587 in healthy volunteers, including single and …

ServiceNow (NOW) Teams Up With TeamViewer As Experian Expands AI Platform Use

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. TeamViewer and ServiceNow (NYSE:NOW) have agreed a multi-year partnership to connect TeamViewer's Digital Employee Experience and Remote Connectivity with the ServiceNow AI Platform. …

Team Inc (TISI) Income Statement

GASS|StealthGas Inc|Price:9.460|Chg%:+0.230

This article provides a comprehensive stock analysis of StealthGas Inc (GASS), highlighting its strong fundamentals, high growth potential, and fair valuation within the Oil & Gas Related Equipment and Services industry. Despite healthy market performance, technical indicators suggest a sideways trading pattern, suitable for …

Peria Karamalai Tea & Produce Co. Ltd. Revenue Breakdown – NSE:PKTEA

StealthGas Inc (GASS) Income Statement

StealthGas Inc. Revenue Breakdown – MUN:S6W

StealthGas Inc. (MUN:S6W) generated 147.43 million EUR in revenue last year, primarily from its Time Charter segment, which contributed 115.07 million EUR. This represents a slight decrease from the previous year's total revenue of 147.63 million EUR. The company's revenue distribution indicates a global …